Apotex Pharmaceuticals Holdings, the Canadian generic pharmaceuticals giant that was founded by Barry Sherman in 1974, has agreed to a takeover.
In a release Wednesday morning, SK Capital Partners LP said it struck a deal to buy Apotex. Terms were not disclosed, and the companies said the transaction is subject to regulatory approvals.
“We are excited to work with SK Capital, whose industry expertise and resources will help grow our leadership in the market and maintain our focus on improving access to high-quality affordable medicines for millions of patients worldwide,” said Apotex president and Chief Executive Officer Jeff Watson in the release.Toronto police identified a suspectBloomberg News reported in November 2021 that Apotex was exploring a sale.
“Apotex is a dynamic, entrepreneurial company with a strong track record of success, underpinned by its diversified product portfolio, robust pipeline of new launches and iconic brand. We feel incredibly privileged to have the opportunity to support Apotex with our deep experience in the pharmaceutical sector,” said SK Capital managing director Aaron Davenport in the release Wednesday.
SK Capital is a New York-based private equity firm that focuses on the pharma, specialty materials, and specialty chemicals industries.According to the release, Rothschild & Co. was Apotex’s financial advisor on the deal, while Davies Ward Phillips & Vineberg was legal counsel.